News | July 07, 2023
Alkem forays into ophthalmology with launch of eye care products
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Supply readiness follows months of manufacturing to ensure timely and ample supply
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Subscribe To Our Newsletter & Stay Updated
